IC 12-15-35 Chapter 35. Drug Utilization Review 12-15-35-1 "Appropriate and medically necessary" defined 12-15-35-2 "Board" defined 12-15-35-3 "Compendia" defined 12-15-35-4 "Counseling" defined 12-15-35-4.5 "Covered outpatient drug" defined 12-15-35-5 "Criteria" defined 12-15-35-6 "Drug-disease contraindication" defined 12-15-35-7 "Drug-drug interaction" defined 12-15-35-8 "Drug utilization review" or "DUR" defined 12-15-35-9 "Intervention" defined 12-15-35-10 "Overutilization or underutilization" defined 12-15-35-11 "Pharmacist" defined 12-15-35-12 "Physician" defined 12-15-35-13 "Prospective DUR" defined 12-15-35-14 "Retrospective DUR" defined 12-15-35-15 "Standards" defined 12-15-35-16 "SURS" defined 12-15-35-17 "Therapeutic appropriateness" defined 12-15-35-17.5 "Therapeutic classification" or "therapeutic category" defined 12-15-35-18 "Therapeutic duplication" defined 12-15-35-18.5 Application of chapter 12-15-35-18.7 Formulary requirements 12-15-35-19 Drug utilization review board; establishment 12-15-35-20 Membership of board 12-15-35-20.1 Conflicts of interest 12-15-35-20.5 Therapeutics committee established; members; limitations; terms; votes; meetings 12-15-35-21 Board; appointment; term 12-15-35-22 Qualifications of board members 12-15-35-23 Physician appointments; geographic balance 12-15-35-24 Reappointment of members 12-15-35-25 Chairman; compensation; expenses 12-15-35-26 Additional staff 12-15-35-27 Retrospective and prospective DUR program responsibility 12-15-35-28 Duties of the board; preferred drug list; report 12-15-35-28.5 Therapeutics committee duties 12-15-35-28.7 Submitting initial preferred drug list; limitations on restrictions; advance notice to providers; implementation; prior authorization limitation; rules 12-15-35-29 Quorum; majority vote on DUR criteria and standards for prescribing 12-15-35-30 Local practices; monitoring 12-15-35-31 Intervention; approval; requisites 12-15-35-32 Repealed 12-15-35-32.1 Annual report contents 12-15-35-33 Repealed 12-15-35-34 Confidential identifying information; release of cumulative nonidentifying information 12-15-35-35 Prior approval program for outpatient drugs; standards 12-15-35-36 Advisory committees 12-15-35-37 Medicaid state plan; inclusion of retrospective and prospective DUR program 12-15-35-38 DUR program guidelines and procedures 12-15-35-39 Retrospective DUR requisites 12-15-35-40 Prospective DUR requisites 12-15-35-41 Board activities under IC 34-30-15 12-15-35-42 Meetings 12-15-35-43 Confidentiality; pharmacist data and information 12-15-35-43.5 Prohibiting the release of proprietary or confidential information obtained under certain circumstances 12-15-35-44 Confidentiality; violations; penalty 12-15-35-45 Outpatient drug formulary; requirements 12-15-35-46 Review of proposed formulary 12-15-35-47 Review of changes to formulary 12-15-35-48 Board review of managed care organization prescription drug program 12-15-35-49 Information provided by office 12-15-35-50 Maximum allowable cost schedule for drugs; pharmacy participation in Medicaid program 12-15-35-51 Advisory committee; duties; report
‹ Prev All Indiana sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.